Celon Pharma公司日前宣布，其PDE10A抑制剂CPL’36的2期临床试验取得积极结果。该药为一种每日一次的创新口服药物，用于治疗帕金森病患者中左旋多巴诱导的运动障碍（LID）。该研究达到了主要终点及多个次要终点，CPL’36在所有衡量帕金森病LID治疗改善的量表上均显示出强力且一致的疗效，效果具有临床意义。

Despite being a mainstay of Parkinson's disease treatment, levodopa, a dopamine-replenishing medication, can cause nasty side ...

Celon Pharma’s PDE10A inhibitor has reduced involuntary movements in a phase 2 trial of individuals with Parkinson’s disease. The Polish biotech tested two daily doses of the drug, dubbed CPL ...